Company
Board of Directors
Bernhard Ehmer
Chairman of the Board of Directors
Mr. Bernhard Ehmer was newly elected as Chairman of the Board of Directors in September 2018. He cur… Read morerently serves as CEO of Biotest AG, and brings more than 30 years of experience from the global pharmaceutical industry to the Company, mainly within oncology.
Jeppe Christiansen, M.Sc.
Deputy Chairman
Jeppe Christiansen has been a member of the Board since 2011 and Deputy Chairman since 2018.
… Read more
He is CEO at Fondsmæglerselskabet Maj Invest A/S, Maj Invest Holding A/S and Emlika ApS. He is also a member of the Executive Management of Maj Invest Equity A/S.
Mr. Christiansen serves as Chairman of Haldor Topsøe A/S, and Vice-Chairman of Novo Nordisk A/S and Maj Bank A/S. He is a board member of Novo Holdings A/S, KIRK- BI A/S, and member of the Board of Governors at Det Kgl. Vajsenhus.
Mr. Christiansen's special competencies with relevance for Symphogen include executive background and extensive experience within the financial sector in relation to financial and capital market issues as well as insight into the investor perspective.
… Read more
He is CEO at Fondsmæglerselskabet Maj Invest A/S, Maj Invest Holding A/S and Emlika ApS. He is also a member of the Executive Management of Maj Invest Equity A/S.
Mr. Christiansen serves as Chairman of Haldor Topsøe A/S, and Vice-Chairman of Novo Nordisk A/S and Maj Bank A/S. He is a board member of Novo Holdings A/S, KIRK- BI A/S, and member of the Board of Governors at Det Kgl. Vajsenhus.
Mr. Christiansen's special competencies with relevance for Symphogen include executive background and extensive experience within the financial sector in relation to financial and capital market issues as well as insight into the investor perspective.
Ron Eastman, MBA
Board member
Ron Eastman has been a member of the Board since 2015.
Mr. Eastman is Managing Direc… Read moretor of EW Healthcare Partners.
He serves as Chairman of EluSys Therapeutics Inc, and is a member of the board of Corium International and IntegenX.
Mr. Eastman's special competencies with relevance for Symphogen include executive and board experience with special focus on building healthcare businesses.
Mr. Eastman is Managing Direc… Read moretor of EW Healthcare Partners.
He serves as Chairman of EluSys Therapeutics Inc, and is a member of the board of Corium International and IntegenX.
Mr. Eastman's special competencies with relevance for Symphogen include executive and board experience with special focus on building healthcare businesses.
John B. Landis, Ph.D.
Board member
John B. Landis has been a member of the Board since 2011.
He is a Director at Exelea… Read mored.
Mr. Landi's special competencies with relevance for Symphogen include scientific and corporate background in pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, and clinical supplies and devices.
He is a Director at Exelea… Read mored.
Mr. Landi's special competencies with relevance for Symphogen include scientific and corporate background in pharmacy, analytical chemistry, process chemistry, biotechnology, quality assurance, and clinical supplies and devices.
Anders Tullgren
Board member
Anders Tullgren was elected member of the Board in April 2018.
Mr. Tullgren current… Read morely serves as Chairman of Xbrane Biopharma, Sweden and is a board member of Trialbee AB, Sweden, and Branding Science Ltd, UK.
Mr. Tullgren's special competencies with relevance for Symphogen include his proven commercial and leadership experiences from 30 years in global pharmaceutical industries.
Mr. Tullgren current… Read morely serves as Chairman of Xbrane Biopharma, Sweden and is a board member of Trialbee AB, Sweden, and Branding Science Ltd, UK.
Mr. Tullgren's special competencies with relevance for Symphogen include his proven commercial and leadership experiences from 30 years in global pharmaceutical industries.
Peter Haahr
Board member
Mr. Peter Haahr was elected member of the Board in September 2018. He currently serves as CFO of Nov… Read moreo Holdings.
Mads Krogsgaard Thomsen
Board member
Mr. Mads Krogsgaard Thomsen was elected member of the Board in September 2018. He currently serves a… Read mores EVP and Chief Science Officer of Novo Nordisk A/S
Søren Lemonius
Board member
Mr. Søren Lemonius was elected member of the Board in September 2018. He currently serves as Managi… Read moreng Partner in the Life Science group of Sunstone Capital and is one of its three co-founders.